Navigation Links
Avandia Lawsuit Settlement News: 'No News is Bad News,' Says Plaintiffs
Date:4/5/2011

NEW YORK, April 5, 2011 /PRNewswire/ -- The latest news on the much publicized Avandia Settlement's is: there is no news.  After a Bloomberg report made public last summer that many of the Avandia suits were coming to a settlement range of approximately $86,000.00 per suit, no new news has come into the market.  This has left many suffering Avandia plaintiffs with more confusion -and concern- when they will actually get their settlement money.

This has led to many Avandia Plaintiffs to seek lawsuit funding in order to receive some cash to pay bills today, prior to getting their actual settlements.  Once industry that tracks the Avandia litigation is the "legal funding industry," where in March one funding company, lawsuitssettlementfunding.com (Legal-Bay LLC), announced a substantial rise in Avandia lawsuit cash advances.  

Dave Kole, CEO of Lawsuitssettlementfunding.com, spoke about the recent developments, "most of our clients tell us the same thing, they are frustrated with the process.  They are confused because there has been no news in the marketplace about how much they will receive, or worse, when they will actually receive their money.  Many of them were notified that they would have answers by the end of the first quarter, but now that we are in April, they simply can't wait any longer.  I only expect more and more Avandia Plaintiffs to seek lawsuit funding each day this drags on."  

Industry experts believe that the Avandia litigation is getting more complex based on the few articles released of late.  

In January GlaxoSmithKline agreed to take a total of a $3.4bil charge on the expected Avandia settlement.  This is an increase from the $2.4bil charge announced last summer.  The increase raises more questions as to the magnitude of the total settlement; and if Avandia will surpass Vioxx as the largest Pharmaceutical settlement in U.S. History.

Also, in February the Louisiana AG Office sued GlaxoSmithKline for civil fraud involving Avandia.  The increase in more litigation involving Avandia –and the subsequent delays- is now only hurting the people most affected by the drug.  And that is the Avandia long suffering plaintiffs and their families waiting for their settlement money.

Contact and Source:
CNJ Enterprises LLC
Chris Janish, CEO
862-485-7655
Email:  cnjenterprisesllc@gmail.com


'/>"/>
SOURCE CNJ Enterprises LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DePuy Hip Recall & Avandia Focus of Nov. 3 Conference, HB Announces
2. GSK Regulatory Update on Avandia Following EMA and FDA Reviews
3. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
4. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
5. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
6. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
7. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
8. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
9. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
10. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
11. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):